市場調査レポート

商品コード

1752817

上皮腫治療の世界市場：疾患タイプ別、治療モダリティ別、エンドユーザー別、地域別、機会、予測、2018年～2032年

Global Epithelioma Treatment Market Assessment, By Disease Type, By Treatment Modality, By End-user, By Region, Opportunities and Forecast, 2018-2032F

出版日: 2025年06月20日
発行: Market Xcel - Markets and Data
ページ情報: 英文 248 Pages
納期: 3～5営業日

カスタマイズ可能

価格

PDF & Excel Printable (Single User License)

USD 4,800 704,256円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 6,000 880,320円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,500 1,247,120円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.72円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の上皮腫治療の市場規模は、2025年～2032年の予測期間中に6.94％のCAGRで拡大し、2024年の49億5,000万米ドルから2032年には84億7,000万米ドルに成長すると予測されています。上皮腫は、上皮組織の細胞から始まるがんの一種であり、一般的には基底細胞がんや扁平上皮がんを通じて皮膚に発生しますが、他の様々な身体部位に発生することもあります。上皮腫治療の世界市場は、症例数の増加、腫瘍学的治療の向上、検出方法の改善により拡大しています。

世界の上皮腫治療市場は、特に基底細胞がん（BCC）と扁平上皮がん（SCC）の有病率の上昇により安定した上昇を達成しています。悪性疾患は、紫外線曝露を経験し、高齢化社会に属する人々に一般的に開発され、世界中で最も多くの非黒色腫皮膚がんを形成しています。標準的な治療法は、外科的切除（モース手術）、放射線療法、外用薬、凍結療法、新しい免疫療法の導入です。現在、医療現場は生物学的治療薬や免疫チェックポイント阻害剤へと移行しており、進行がん症例では標準治療よりも優れていることが証明されています。北米が市場をリードしているのは、その高い診断統計と優れたヘルスケアシステムに加え、画期的な治療法の迅速な導入によるものです。北米に次いで欧州が市場シェアで2位につけており、アジア太平洋は最も成長率の高い地域として発展しています。治療費とヘルスケアへのアクセスは、発展途上国にとって大きな障害となっています。市場の着実な成長を支えているのは、研究の進展と早期発見に関する社会教育の拡大です。今後の治療の見通しは、個別化医療のコンセプトと、現在開発段階にある二重治療薬に左右されるものとみられています。

上皮腫治療市場は多くの患者に貢献しています。例えば、米国がん協会のデータによると、2023年10月には、米国で毎年約540万人が新たに基底細胞がんと扁平上皮がんに罹患しています。基底細胞がんは全症例の80％を占め、毎年430万人の新規患者に達し、BCCがいかに非黒色腫皮膚がん治療市場をリードしているかを示しながら、重い疾患負荷を実証しています。

当レポートでは、世界の上皮腫治療市場について調査し、市場の概要とともに、疾患タイプ別、治療モダリティ別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

市場規模分析と予測
市場シェア分析と予測
- 疾患タイプ別
  - 基底細胞上皮腫
  - 扁平上皮腫
  - その他の上皮腫の種類
- 治療モダリティ別
  - 薬物療法
  - 外科手術
  - 放射線治療
  - 光線力学療法
  - 併用療法
- エンドユーザー別
  - 病院
  - 専門クリニック
  - 外来手術センター
  - 研究・学術機関
- 地域別
  - 北米
  - 欧州
  - アジア太平洋
  - 南米
  - 中東・アフリカ
- 企業別市場シェア分析（上位5社およびその他- 金額別、2024年）
2024年の市場マップ分析

第6章北米の上皮腫治療市場の見通し、2018年～2032年

市場規模分析と予測
市場シェア分析と予測
国別市場評価
- 米国
- カナダ
- メキシコ

第7章欧州の上皮腫治療市場の見通し、2018年～2032年

ドイツ
フランス
イタリア
英国
ロシア
オランダ
スペイン
トルコ
ポーランド

第8章アジア太平洋の上皮腫治療市場の見通し、2018年～2032年

インド
中国
日本
オーストラリア
ベトナム
韓国
インドネシア
フィリピン

第9章南米の上皮腫治療市場の見通し、2018年～2032年

ブラジル
アルゼンチン

第10章中東・アフリカの上皮腫治療市場の見通し、2018年～2032年

サウジアラビア
アラブ首長国連邦
南アフリカ

第11章需要供給分析

第12章バリューチェーン分析

第13章ポーターのファイブフォース分析

第14章 PESTLE分析

第15章価格分析

第16章市場力学

市場の促進要因
市場の課題

第17章市場動向と発展

第18章規制の枠組み

臨床試験
規制当局の承認

第19章特許の情勢

第20章ケーススタディ

第21章競合情勢

市場リーダートップ5の競合マトリックス
参入企業トップ5のSWOT分析
市場の主要企業トップ10の情勢
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche AG
- Novartis AG
- Sanofi S.A.
- Pfizer Inc.
- Regeneron Pharmaceuticals
- Sun Pharmaceutical Industries Limited
- Eli Lilly and Company
- BeOne Medicines, Ltd.

第22章戦略的提言

第23章調査会社について・免責事項

図表

List of Tables

Table 1. Competition Matrix of Top 5 Market Leaders
Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 2. Global Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 3. Global Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 4. Global Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 5. Global Epithelioma Treatment Market Share (%), By Region, 2018-2032F
Figure 6. North America Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 7. North America Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 8. North America Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 9. North America Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 10. North America Epithelioma Treatment Market Share (%), By Country, 2018-2032F
Figure 11. United States Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 12. United States Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 13. United States Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 14. United States Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 15. Canada Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 16. Canada Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 17. Canada Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 18. Canada Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 19. Mexico Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 20. Mexico Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 21. Mexico Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 22. Mexico Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 23. Europe Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 24. Europe Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 25. Europe Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 26. Europe Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 27. Europe Epithelioma Treatment Market Share (%), By Country, 2018-2032F
Figure 28. Germany Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 29. Germany Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 30. Germany Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 31. Germany Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 32. France Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 33. France Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 34. France Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 35. France Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 36. Italy Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 37. Italy Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 38. Italy Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 39. Italy Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 40. United Kingdom Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 41. United Kingdom Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 42. United Kingdom Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 43. United Kingdom Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 44. Russia Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 45. Russia Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 46. Russia Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 47. Russia Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 48. Netherlands Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 49. Netherlands Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 50. Netherlands Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 51. Netherlands Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 52. Spain Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 53. Spain Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 54. Spain Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 55. Spain Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 56. Turkey Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 57. Turkey Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 58. Turkey Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 59. Turkey Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 60. Poland Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 61. Poland Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 62. Poland Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 63. Poland Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 64. South America Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 65. South America Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 66. South America Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 67. South America Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 68. South America Epithelioma Treatment Market Share (%), By Country, 2018-2032F
Figure 69. Brazil Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 70. Brazil Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 71. Brazil Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 72. Brazil Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 73. Argentina Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 74. Argentina Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 75. Argentina Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 76. Argentina Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 77. Asia-Pacific Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 78. Asia-Pacific Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 79. Asia-Pacific Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 80. Asia-Pacific Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 81. Asia-Pacific Epithelioma Treatment Market Share (%), By Country, 2018-2032F
Figure 82. India Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 83. India Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 84. India Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 85. India Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 86. China Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 87. China Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 88. China Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 89. China Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 90. Japan Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 91. Japan Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 92. Japan Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 93. Japan Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 94. Australia Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 95. Australia Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 96. Australia Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 97. Australia Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 98. Vietnam Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 99. Vietnam Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 100. Vietnam Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 101. Vietnam Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 102. South Korea Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 103. South Korea Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 104. South Korea Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 105. South Korea Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 106. Indonesia Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 107. Indonesia Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 108. Indonesia Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 109. Indonesia Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 110. Philippines Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 111. Philippines Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 112. Philippines Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 113. Philippines Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 114. Middle East & Africa Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 115. Middle East & Africa Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 116. Middle East & Africa Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 117. Middle East & Africa Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 118. Middle East & Africa Epithelioma Treatment Market Share (%), By Country, 2018-2032F
Figure 119. Saudi Arabia Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 120. Saudi Arabia Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 121. Saudi Arabia Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 122. Saudi Arabia Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 123. UAE Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 124. UAE Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 125. UAE Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 126. UAE Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 127. South Africa Epithelioma Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 128. South Africa Epithelioma Treatment Market Share (%), By Disease Type, 2018-2032F
Figure 129. South Africa Epithelioma Treatment Market Share (%), By Treatment Modality, 2018-2032F
Figure 130. South Africa Epithelioma Treatment Market Share (%), By End-user,2018-2032F
Figure 131. By Disease Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
Figure 132. By Treatment Modality Map-Market Size (USD Billion) & Growth Rate (%), 2024
Figure 133. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2024
Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024

Product Code: MX13405

Global epithelioma treatment market is projected to witness a CAGR of 6.94% during the forecast period 2025-2032, growing from USD 4.95 billion in 2024 to USD 8.47 billion in 2032. Epithelioma is a form of cancer that begins in the cells of epithelial tissue and commonly affects the skin through basal cell carcinoma and squamous cell carcinoma, while it may arise in various other body parts. The worldwide market for treating epithelioma is expanding because of the climbing number of cases and better oncology treatments, and improved detection practices.

The global market for epithelioma treatment achieves a stable rise owing to an increasing disease prevalence, especially basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Malignant diseases commonly develop in people who experience UV exposure and belong to aging populations to form the largest number of non-melanoma skin cancers throughout the world. The standard treatment protocols consist of surgical excision (Mohs surgery) along with radiation therapy and topical medications, together with cryotherapy and the introduction of new immunotherapies. The medical field currently transitions toward biological therapy drugs and immune checkpoint inhibitors, which prove better than standard treatments in advanced cancer cases. North America leads the market because of its elevated diagnosis statistics and superior healthcare system, coupled with a rapid implementation of groundbreaking treatment methods. Following North America, Europe comes in second place in market share, while Asia-Pacific develops as the region with the highest growth rate. Treatment expenses and healthcare access pose major obstacles for developing countries. The combination of growing research and expanding public education on early disease identification maintains the market's steady growth. The upcoming therapeutic landscape will depend on personalized medicine concepts, along with dual therapy drugs that are now advancing through development phases.

The market for epithelioma treatment serves numerous patients. For instance, in October 2023, according to the American Cancer Society data, approximately 5.4 million new basal and squamous cell skin cancer cases were diagnosed annually in the United States. Basal cell carcinomas represent 80% of the total cases, which reach 4.3 million new patients each year to demonstrate the heavy disease load while showing how BCC leads the non-melanoma skin cancer therapeutic market.

Increasing Prevalence of Skin Care Support Market Expansion

The expanding global epithelioma treatment market experiences strong growth due to both rising skin care issues and growing cases of this skin cancer type. The rising public understanding of skin health drives people to obtain preventive and therapeutic approaches, which creates a higher demand for advanced medical treatments. Extended sun exposure, alongside environmental pollution and poor lifestyle choices, creates a growing number of skin disorders that drive market growth. The development of targeted drug therapies, together with immunotherapy and minimally invasive procedures, produces enhanced results and higher patient recovery rates in dermatological treatments. Multiple governments, together with healthcare organizations, allocate funds for skin cancer awareness programs that promote timely diagnosis and treatment. The market receives benefits from growing healthcare funding and expanded availability of medical facilities across the globe. The epithelioma treatment market will experience substantial growth during the upcoming years, owing to an increasing skin care focus and early disease detection, which creates fresh business prospects for pharmaceutical companies and healthcare providers to serve unmet patient requirements.

For instance, the Skin Cancer Foundation Photobiology Committee revealed updated requirements for the Seal of Recommendation during May 2025, which assesses products that deliver safe and effective protection from both UVA and UVB ultraviolet radiation that cause skin cancer.

Technological Advancement Increases Market Demand

The global market for epithelioma treatment is expected to experience a substantial increase in demand due to technological progress, which improves medical precision while enhancing therapeutic success and making healthcare more accessible. The combination of AI-powered diagnostic systems with targeted immunotherapies and laser-based robotic surgical methods delivers better treatment results and shorter recovery periods. The medical field now offers promising alternatives to conventional therapy through PD-1 inhibitors and mRNA-based vaccines, while liquid biopsies and confocal microscopy provide precise early diagnosis. Specialized healthcare becomes more accessible to underserved regions through telemedicine and wearable health technology. The improved patient survival rates and rising market demand result from the availability of advanced personalized treatments.

Additionally, to support technological advancement in epithelioma treatment, government bodies also take initiatives to promote treatment by giving approvals. For instance, in December 2024, the Food and Drug Administration granted approval to Unloxcyt (Checkpoint Therapeutics, Inc.) which functions as a programmed death ligand-1 (PD-L1) blocking antibody for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who require an alternative to curative surgery or curative radiation.

Basal Cell Carcinoma Holds Largest Market Share

Basal cell carcinoma (BCC) holds the largest market segment in the global epithelioma treatment market, driven by its status as the most frequently diagnosed form of skin cancer. The market leadership of BCC exists because of two main factors: increased cases from long-term UV damage and population aging, together with improved diagnostic techniques. The market expands because patients have multiple treatment options, which include surgical removal, together with radiation therapy and topical therapy, and targeted drug treatments. The commercial success of BCC receives an additional boost from rising healthcare funding and strong dermatological therapy research and development activities, and beneficial reimbursement frameworks in advanced territories.

Additionally, for the prevention of BCC, companies are continuously innovating new products to improve the quality of life for BCC affected patients. For instance, in March 2024, Sol-Gel Technologies Ltd., a clinical-stage dermatology company focused on developing innovative treatments for severe skin conditions, announced its full-year 2023 financial results and provided a corporate update. The company is currently conducting a Phase 3 clinical trial of SGT-610, an Orphan Drug candidate that could become the first therapy to prevent new basal cell carcinomas in patients with Gorlin syndrome.

North America Dominates the Epithelioma Treatment Market Size

North America asserts its dominance in the epithelioma treatment sector through several complementary elements. The region experiences greater amounts of skin cancer cases because of its high ultraviolet radiation exposure and its older demographic. The region's state-of-the-art healthcare facilities enable the introduction of novel medical treatments, including immunotherapies and targeted therapies. Major pharmaceutical companies, together with research centers, operate clinical trials that accelerate the creation of new therapeutic methods. The Food and Drug Administration applies regulatory standards that quicken the medical treatment approval process. The combination of high healthcare expenditures by patients and broad insurance coverage in North America enables them to receive the most advanced medical treatments. Public awareness programs in the region drive better early detection efforts and treatment adherence, which keeps North America as the dominant market.

Additionally, the substantial disease burden of North America drives its leadership position in epithelioma treatment. For instance, according to the American Academy of Dermatology (AAD) estimate, the region is expected to diagnose approximately 107,240 noninvasive and 104,960 invasive melanoma cases in 2025. The high disease rates in the region stimulate the rapid implementation of new treatments within its advanced healthcare facilities.

Impact of U.S. Tariffs on the Global Epithelioma Treatment Market

The U.S. tariffs have caused significant disruptions in the global market for epithelioma treatment by driving up expenses for imported pharmaceuticals and healthcare equipment. Medical treatments now cost more because of increased expenses, particularly affecting developing country populations, which require budget-friendly healthcare options. The interruptions in supply chains result in patients missing their medical treatments at proper times, which produces inferior treatment outcomes. Export cost increases will probably make manufacturers reduce their medical treatment development investments, so this will slow down progress in this field. The implementation of tariff retaliation could block American patients from obtaining foreign-developed advanced medical treatments. Patients living in low-income areas face a double threat of financial and logistical barriers, which could prevent them from obtaining essential medical care. Cancer treatment accessibility requires trade policies to address the unintended consequences that occur in this field. Economic objectives must align strategically with medical requirements to drive forward global epithelioma treatment development.

Key Players Landscape and Outlook

The successful companies operating in the epithelioma treatment market differentiate themselves by creating new therapies and forming strategic alliances while investing more in research and development. The focus of market leaders is on developing immunotherapy and targeted treatments to enhance medical outcomes and patient health. Emerging companies in the field establish themselves by offering budget-friendly treatments together with groundbreaking delivery techniques. Market competition will be shaped by future developments in both innovation and accessibility; these factors determine market outcomes.

For instance, in September 2024, Merck & Co., Inc. received approval from the Food and Drug Administration for KEYTRUDA to treat mesothelioma, which underscores the rising significance of immunotherapy for epithelial cancers.

For instance, in January 2025, Regeneron Pharmaceuticals strengthened its position in the epithelioma treatment market when its Phase 3 C-POST trial demonstrated Libtayo achieved statistically significant improvement in disease-free survival for high-risk cutaneous squamous cell carcinoma patients, marking an important advancement in adjuvant immunotherapy options for post-surgical CSCC treatment.

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Epithelioma Treatment Market Outlook, 2018-2032F

5.1. Market Size Analysis & Forecast
- 5.1.1. By Value
5.2. Market Share Analysis & Forecast
- 5.2.1. By Disease Type
  - 5.2.1.1. Basal Cell Epithelioma
  - 5.2.1.2. Squamous Cell Epithelioma
  - 5.2.1.3. Other Epithelioma Types
- 5.2.2. By Treatment Modality
  - 5.2.2.1. Drug Therapy
    - 5.2.2.1.1. Hedgehog Pathway Inhibitors
    - 5.2.2.1.2. Immune Checkpoint Inhibitors
    - 5.2.2.1.3. Chemotherapeutic Agents
    - 5.2.2.1.4. Other Drug Classes
  - 5.2.2.2. Surgical Procedures
    - 5.2.2.2.1. Mohs Micrographic Surgery
    - 5.2.2.2.2. Cryosurgery
    - 5.2.2.2.3. Excisional Surgery
  - 5.2.2.3. Radiation Therapy
  - 5.2.2.4. Photodynamic Therapy
  - 5.2.2.5. Combination Therapies
- 5.2.3. By End-user
  - 5.2.3.1. Hospitals
  - 5.2.3.2. Specialty Clinics
  - 5.2.3.3. Ambulatory Surgical Centers
  - 5.2.3.4. Research and Academic Institutes
- 5.2.4. By Region
  - 5.2.4.1. North America
  - 5.2.4.2. Europe
  - 5.2.4.3. Asia-Pacific
  - 5.2.4.4. South America
  - 5.2.4.5. Middle East and Africa
- 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
5.3. Market Map Analysis, 2024
- 5.3.1. By Disease Type
- 5.3.2. By Treatment Modality
- 5.3.3. By End-user
- 5.3.4. By Region

6. North America Epithelioma Treatment Market Outlook, 2018-2032F

6.1. Market Size Analysis & Forecast
- 6.1.1. By Value
6.2. Market Share Analysis & Forecast
- 6.2.1. By Disease Type
  - 6.2.1.1. Basal Cell Epithelioma
  - 6.2.1.2. Squamous Cell Epithelioma
  - 6.2.1.3. Other Epithelioma Types
- 6.2.2. By Treatment Modality
  - 6.2.2.1. Drug Therapy
    - 6.2.2.1.1. Hedgehog Pathway Inhibitors
    - 6.2.2.1.2. Immune Checkpoint Inhibitors
    - 6.2.2.1.3. Chemotherapeutic Agents
    - 6.2.2.1.4. Other Drug Classes
  - 6.2.2.2. Surgical Procedures
    - 6.2.2.2.1. Mohs Micrographic Surgery
    - 6.2.2.2.2. Cryosurgery
    - 6.2.2.2.3. Excisional Surgery
  - 6.2.2.3. Radiation Therapy
  - 6.2.2.4. Photodynamic Therapy
  - 6.2.2.5. Combination Therapies
- 6.2.3. By End-user
  - 6.2.3.1. Hospitals
  - 6.2.3.2. Specialty Clinics
  - 6.2.3.3. Ambulatory Surgical Centers
  - 6.2.3.4. Research and Academic Institutes
- 6.2.4. By Country Share
  - 6.2.4.1. United States
  - 6.2.4.2. Canada
  - 6.2.4.3. Mexico
6.3. Country Market Assessment
- 6.3.1. United States Epithelioma Treatment Market Outlook, 2018-2032F*
  - 6.3.1.1. Market Size Analysis & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share Analysis & Forecast
    - 6.3.1.2.1. By Disease Type
      - 6.3.1.2.1.1. Basal Cell Epithelioma
      - 6.3.1.2.1.2. Squamous Cell Epithelioma
      - 6.3.1.2.1.3. Other Epithelioma Types
    - 6.3.1.2.2. By Treatment Modality
      - 6.3.1.2.2.1. Drug Therapy
      - 6.3.1.2.2.1.1. Hedgehog Pathway Inhibitors
      - 6.3.1.2.2.1.2. Immune Checkpoint Inhibitors
      - 6.3.1.2.2.1.3. Chemotherapeutic Agents
      - 6.3.1.2.2.1.4. Other Drug Classes
      - 6.3.1.2.2.2. Surgical Procedures
      - 6.3.1.2.2.2.1. Mohs Micrographic Surgery
      - 6.3.1.2.2.2.2. Cryosurgery
      - 6.3.1.2.2.2.3. Excisional Surgery
      - 6.3.1.2.2.3. Radiation Therapy
      - 6.3.1.2.2.4. Photodynamic Therapy
      - 6.3.1.2.2.5. Combination Therapies
    - 6.3.1.2.3. By End-user
      - 6.3.1.2.3.1. Hospitals
      - 6.3.1.2.3.2. Specialty Clinics
      - 6.3.1.2.3.3. Ambulatory Surgical Centers
      - 6.3.1.2.3.4. Research and Academic Institutes
- 6.3.2. Canada
- 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Epithelioma Treatment Market Outlook, 2018-2032F

7.1. Germany
7.2. France
7.3. Italy
7.4. United Kingdom
7.5. Russia
7.6. Netherlands
7.7. Spain
7.8. Turkey
7.9. Poland

8. Asia-Pacific Epithelioma Treatment Market Outlook, 2018-2032F

8.1. India
8.2. China
8.3. Japan
8.4. Australia
8.5. Vietnam
8.6. South Korea
8.7. Indonesia
8.8. Philippines

9. South America Epithelioma Treatment Market Outlook, 2018-2032F

9.1. Brazil
9.2. Argentina

10. Middle East and Africa Epithelioma Treatment Market Outlook, 2018-2032F

10.1. Saudi Arabia
10.2. UAE
10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

16.1. Market Drivers
16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework

18.1. Clinical Trials
18.2. Regulatory Approvals

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

21.1. Competition Matrix of Top 5 Market Leaders
21.2. SWOT Analysis for Top 5 Players
21.3. Key Players Landscape for Top 10 Market Players
- 21.3.1. Merck & Co., Inc.
  - 21.3.1.1. Company Details
  - 21.3.1.2. Key Management Personnel
  - 21.3.1.3. Products and Services
  - 21.3.1.4. Financials (As Reported)
  - 21.3.1.5. Key Market Focus and Geographical Presence
  - 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
- 21.3.2. Bristol-Myers Squibb Company
- 21.3.3. F. Hoffmann-La Roche AG
- 21.3.4. Novartis AG
- 21.3.5. Sanofi S.A.
- 21.3.6. Pfizer Inc.
- 21.3.7. Regeneron Pharmaceuticals
- 21.3.8. Sun Pharmaceutical Industries Limited
- 21.3.9. Eli Lilly and Company
- 21.3.10. BeOne Medicines, Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

上皮腫治療の世界市場：疾患タイプ別、治療モダリティ別、エンドユーザー別、地域別、機会、予測、2018年～2032年

Global Epithelioma Treatment Market Assessment, By Disease Type, By Treatment Modality, By End-user, By Region, Opportunities and Forecast, 2018-2032F

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国の関税の影響

第4章 エグゼクティブサマリー

第5章 世界上皮腫治療市場の見通し、2018年～2032年

第6章 北米の上皮腫治療市場の見通し、2018年～2032年

第7章 欧州の上皮腫治療市場の見通し、2018年～2032年

第8章 アジア太平洋の上皮腫治療市場の見通し、2018年～2032年

第9章 南米の上皮腫治療市場の見通し、2018年～2032年

第10章 中東・アフリカの上皮腫治療市場の見通し、2018年～2032年

第11章 需要供給分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析